Aziz K M
Ministry of Health, Riyadh, Saudi Arabia.
Saudi J Kidney Dis Transpl. 1995 Jul-Sep;6(3):271-4.
Data on incidence and prevalence rates of end-stage renal disease (ESRD) from selected countries including Saudi Arabia are provided. Current data from this country suggest that the incidence of treated ESRD (t-ESRD) in the age-group 0-20 years is 14 per million population (PMP) while the combined incidence for all ages is 240 PMP. The cost of management of the patients is staggering. In Japan, it has been estimated that the projected prevalence of t-ESRD will be 1111 PMP needing an estimated budget of US $ 5.8 billion per year for their management. Globally, more than US $ 50 billion would be needed per year with the presently available treatment modalities. This financial liability might make "Health for all by the year 2000" a myth unless some cheaper method of treatment is made available. Vigorous research is needed towards identifying and prioritizing vulnerable groups for ESRD by identifying and properly managing at-risk groups. These include patients with diabetes mellitus and hypertension as well as patients with indicators like proteinuria and obstructive uropathy. Cheaper modes of renal replacement therapy should be sought. Interesting ideas such as induction of diarrhea for amelioration of renal failure need to be explored further as also the use of the patient's own intestine as a medium for molecular exchange.
提供了包括沙特阿拉伯在内的部分国家终末期肾病(ESRD)的发病率和患病率数据。该国目前的数据表明,0至20岁年龄组中接受治疗的终末期肾病(t-ESRD)发病率为每百万人口14例(PMP),而所有年龄段的综合发病率为240 PMP。患者的管理成本惊人。在日本,据估计,t-ESRD的预计患病率将为1111 PMP,每年管理这些患者估计需要58亿美元的预算。在全球范围内,采用目前可用的治疗方式每年将需要超过500亿美元。除非能找到更便宜的治疗方法,否则这笔经济负担可能会使“2000年人人享有健康”成为一个神话。需要大力开展研究,通过识别和妥善管理高危人群来确定ESRD的弱势群体并确定其优先顺序。这些人群包括糖尿病和高血压患者以及有蛋白尿和梗阻性尿路病等指标的患者。应寻求更便宜的肾脏替代治疗方式。像通过诱导腹泻改善肾衰竭这样有趣的想法以及利用患者自身肠道作为分子交换介质的方法都需要进一步探索。